Neuronal survival and axonal regrowth obtained in vitro

Repair of the central nervous system and restoration of voluntary motor activity through axonal re-growth has long been considered impossible in mammals. Over the last decade, numerous attempts proved disappointing overall. The Inserm team led by Alain Privat has recently shown that an essential component interfering with regeneration was due to the activity of astrocytes, feeder cells that surround neurons.

Normally, the primary role of astrocytes is to supply the nutrients necessary for neuronal function. In the event of spinal injury or lesion, astrocytes synthesize two particular proteins (glial fibrillary acidic protein (GFAP) and vimentin), which isolate the damaged neuron to prevent interference with the operation of the central nervous system.

While the protection is initially useful, in the long run it induces formation of impermeable cicatricial tissue around the neuron, thus constituting impenetrable scarring hostile to axonal regeneration and hence to propagation of nervous impulses. In the event of severe injury, the scarring engenders motor paralysis.

On the basis of the initial findings, the researchers pursued a strategy aimed at developing a therapeutic instrument to block formation of cicatricial tissue. In order to do so, they used gene therapy based on use of interfering RNA. The short RNA sequences, which were made to measure, were inserted into the cytoplasm of cultured astrocytes using a viral therapeutic vector. Once in the cell, the RNA activates mechanisms which block the synthesis of the two proteins secreted by astrocytes and responsible for cicatrix formation. Using that technique, the researchers succeeded in controlling the reaction of astrocytes and when the latter were cultured with neurons, they promoted neuronal survival and triggered axonal growth.

The promising results are now to be validated by in vivo studies. The next stage of the work, currently ongoing, applies the same method to the mouse. The approach may be used in the future in patients having undergone spinal injury.

Find out more:

Source

A novel and efficient gene transfer strategy reduces glial scarring and improves neuronal survival and axonal growth in vitro

Desclaux Mathieu1, Teigell Marisa 2, Amar Lahouari1, Vogel Roland1, Gimenez y Ribotta Minerva3, Privat Alain4 and Mallet Jacques1

1 : Biotechnology and Biotherapy Group, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere, Centre National de la Recherche Scientifique (CNRS) UMR 7225, Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS 975, Université Pierre et Marie Curie (UPMC) – Hôpital de la Pitié Salpêtrière, Paris F-75013, France.

2 : NEUREVA-inc., Montpellier F-34091 cedex 5, France.

3 : Consejo Superior de Investigationes Cientifícas (CSIC), Universidad Miguel Hernández (UMH), Instituto de Neurociencias de Alicante, Campus de San Juan., Sant Joan D'Alacant Nacional 332, E-03550, España

4 : Institut National de la Santé et de la Recherche Médicale (INSERM) U583, Physiopathologie et Thérapie des Déficits Sensoriels et Moteurs, Institut des Neurosciences de Montpellier (INM), Université Montpellier 2, Montpellier F-34091 cedex 5, France.

Researcher contacts
Alain Privat
Directeur de recherche Inserm
Unité 583 « physiopathologie et thérapie des déficits sensoriels et moteurs »
Email : privat@univ-montp2.fr
Tel : 04 99 63 60 06
Jacques Mallet
Directeur de recherche CNRS
Centre de recherche de l'institut du cerveau et de la moelle épinière
Email : jacques.mallet@upmc.fr
Tel : 01 42 17 75 30
Press contact
Inserm – Priscille Rivière
Email : presse@inserm.fr
Tel : 01 44 23 60 97